| Volume: | 47,100,778 |
|---|---|
| Day's Low: | $17.65 |
| 52-wk Low: | $11.62 |
| Previous Close: | $17.84 |
| Dividend: | $0.18 |
| Market Cap: | 143,960,500 |
| Avg Volume: | 50,835,900 |
|---|---|
| Day's High: | $18.15 |
| 52-wk High: | $20.36 |
| Open Price: | $17.87 |
| Yield: | 4.04% |
| P/E (Forward): | 8.15 |
| 12:18 PM | 2/9/2010 | UPDATE: Ratiopharm Shortlist Expected Early Next Week - Sources |
| 11:35 AM | 2/9/2010 | UPDATE: Biogen 4Q Profit Up 48%; Offers Bright 2010 Forecast |
| 11:14 AM | 2/9/2010 | Ratiopharm Shortlist Expected Early Next Week - Sources |
| 11:08 PM | 2/7/2010 | UPDATE: CIC: US Stock Holdings Valued At $9.63 Billion End-2009 |
| 5:43 PM | 2/5/2010 | Biogen Plans First Study For Earlier Use Of MS Drug Tysabri |
| 4:19 PM | 2/5/2010 | NY Fed: JPMorgan's Dimon, Pfizer's Kindler Re-Elected To Board |
| 9:13 AM | 2/4/2010 | Four Bidders Remain In Race For Merckle's Ratiopharm -Source |
| 2/9/2010 | Republicans and Democrats will debate on TV, but little may come of it. (The Motley Fool) |
| 2/9/2010 | And where to look for other "black swans." (The Motley Fool) |
| 2/9/2010 | Avoid a few key mistakes, and you'll lose less money. (The Motley Fool) |
| 2/9/2010 | Discount cards for drugs help Pfizer track patients' use. (The Motley Fool) |
| 2/9/2010 | Go from good to great. (The Motley Fool) |
| 2/9/2010 | Do it yourself and know what you're getting. (The Motley Fool) |
| 2/9/2010 | Market-trouncing returns could be written in these five stars. (The Motley Fool) |
| 2/9/2010 | Cholesterol Drug Approved for People Without High Cholesterol (WSJ.com) |
| Most Recent Quarter ($) | Same Quarter Last Year ($) | % Change | |
| EPS, Pro Forma | 0.49 | 0.65 | -24.62 |
| EPS, GAAP | 0.07 | 0.04 | 75.00 |
| Consensus Estimate | 0.49 | 0.60 | -18.33 |
| Trailing 12 Months | Year-Earlier Period | % Change | |
| EPS, Pro Forma | 2.02 | 2.02 | 0.00 |
| EPS, GAAP | 1.21 | 1.20 | 0.83 |
| Consensus Estimate | 1.91 | NA | NA |
| PFE | Industry Average | |
| P/E (TTM) | 14.74 | 14.70 |
| P/E (Forward) | 8.15 | 12.60 |
| PEG Ratio | 4.43 | 1.45 |
| Price/Sales | 2.63 | 2.51 |
| Beta | 0.73 | 0.74 |